Lower frontal amyloid burden in antidepressant users: preliminary findings from persons with and without post-traumatic stress disorder in the adni dod study

Noelle Snyder,Kewei Chen,Ji Luo,Pradeep Thiyyagura,Vivek Devadas,Yinghua Chen,Robert Bauer,Yvette I. Sheline,William J. Jagust,Thomas Neylan,Susan M. Landau,Michael W. Weiner,Eric M. Reiman

DOI: https://doi.org/10.1016/j.jalz.2016.06.1042

2016-01-01

Abstract:Florbetapir PET images were used to compare cerebral amyloid burden in participants with post-traumatic stress disorder (PTSD) and in control subjects without PTSD or history of traumatic brain injury. Since PTSD participants had suggestive evidence of lower (not higher) standard uptake value ratios (SUVRs) than the controls in the frontal cortex, since antidepressants are commonly used in persons with PTSD, and since serotonin-reuptake inhibitors (SSRIs) have been shown to be associated with cerebrospinal fluid and PET evidence of lower amyloid accumulation (Cirrito, 2011; Sheline, 2014), post-hoc analyses were performed to investigate the possibility that these findings are attributable to antidepressant use. Mean cerebral-to-cerebellar SUVRs, an amyloid positive threshold of 1.18 consistent with moderate-to-severe amyloid plaques (Fleisher, 2011), and statistical brain maps (SPM) were used to compare florbetapir PET scans from 52 male participants with PTSD (68±4 years old, 4 with mild cognitive impairment [MCI]) and 52 male controls (71±6 years old, 2 with MCI). Post-hoc analyses were performed to determine whether regional SUVR differences are attributable to antidepressant use in 24 PTSD patients (including 15 on an SSRI) and 3 controls (including 1 on an SSRI). PTSD and control groups did not differ in their mean cerebral SUVRs corrected for age and education (P=0.18; P=0.04 without age/education correction). However, the PTSD group had a significantly lower percentage of amyloid positive participants (PTSD: 3.8%, NC: 19.2%; P=0.01). Brain maps revealed significantly lower regional SUVRs in the PTSD group, primarily in the frontal cortex (P<0.005, corrected for age and education, uncorrected for multiple comparisons). Regional differences were no longer apparent after correction for antidepressant use. Furthermore, antidepressant users were distinguished from non-users by significantly lower frontal SUVRs (uncorrected P<0.005), a significantly lower percentage of amyloid positive subjects (users: 0%, non-users: 15.6%; P=0.03), and a significantly greater proportion of cerebral voxels with lower SUVRs (Monte-Carlo Simulation, P<0.001). While preliminary, our findings suggest that adults with PTSD have less fibrillar amyloid and that this reduction may be at least partly attributable to antidepressant use. They support the possibility that antidepressants are associated with reduced amyloid plaque burden and with a lower risk of AD.